Introduction
In the management of inflammatory bowel disease (IBD) there are a variety of immunosuppressive drugs that have been shown to achieve control of symptoms and keep patients in remission, which is the primary goal of treatment, thus avoiding the continued use of corticosteroids.
One such Immunomodulators drug is Azathioprine, which is an analog of purines and consequently is incorporated into cellular DNA by the active metabolite, Mercaptopurine. This achieves inhibition of multiple pathways in the biosynthesis of nucleic acids and to a lesser extent causes some "damage" to the DNA through the incorporation of purine thio-analogues. Chronic use of Immunomodulator drugs has been reported to increase the risk of developing some tumors, which in turn increases the risk per se of IBD patients having other malignancies.
Clinical Case
A 78-year-old male farmer (he has worked for over 40 years), frequent smoker with the following personal history: arterial hypertension, cerebrovascular disease, pacemaker since 2010, higher risk of non-melanoma skin tumors such as squamous cell carcinoma in patients taking these drugs, as indeed in our case.
In this case several risk factors for developing malignancies were observed, such as: IBD, smoking, continuous sun exposure and chronic use of immunomodulators. In this patient the treatment of skin lesions was removing the involved drug, cryotherapy and surgical resection with good response. Unfortunately, the patient died months later due to underlying conditions. Therefore, it is important to monitor patients with IBD receiving immunomodulators therapy for skin lesions, especially if they also have additional risk factors like in this case, with a history of smoking and sun exposure. So that, it is of utmost importance to advise patients on Immunomodulator therapy to examine themselves and use sunscreen, avoiding unnecessary UV exposures.
Finally, it is also necessary to share this knowledge to other professionals upon detecting skin lesions associated with the use of Immunomodulators in IBD patients. In this regard an article has recently been published by Okafor et al. [6] concluding that all patients with inflammatory bowel disease with or without immunosuppressants must undergo annual skin cancer screening as a cost-effective intervention.
nasal pyramid was distinguished (Figure 2) . It was only then that his gastroenterologist became involved again and the immunosuppressive therapy (Azathioprine) was stopped immediately. After the withdrawal of Azathioprine the patient presented a mild outbreak which improved with Prednisone. Further surgical resection of the most prominent facial lesion was carried out. The final pathological diagnosis was of squamous cell carcinoma. The patient died five months later due to cardiopulmonary complications.
Discussion
The chronic use of Immunomodulators in IBD is justified to try to keep the patient in remission thus avoiding the use of corticosteroids [1] . However, chronic use of Immunomodulators have been associated with the risk of developing lymphoma and nonmelanoma skin cancer (Table 1) [2] [3] [4] . Thus Peyrin et al. [5] have described a
